NONALCOHOLIC STEATOHEPATITIS (NASH)
Clinical trials for NONALCOHOLIC STEATOHEPATITIS (NASH) explained in plain language.
Never miss a new study
Get alerted when new NONALCOHOLIC STEATOHEPATITIS (NASH) trials appear
Sign up with your email to follow new studies for NONALCOHOLIC STEATOHEPATITIS (NASH), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug shows promise against fatty liver disease in Mid-Stage trial
Disease control OngoingThis study tests an experimental drug called miricorilant in 175 adults with nonalcoholic steatohepatitis (NASH), a serious fatty liver disease. Participants are randomly assigned to receive either the drug or a placebo, and researchers measure changes in liver fat using MRI scan…
Matched conditions: NONALCOHOLIC STEATOHEPATITIS (NASH)
Phase: PHASE2 • Sponsor: Corcept Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New drug aramchol aims to reverse fatty liver damage in phase 3 trial
Disease control TerminatedThis study tests a drug called Aramchol for people with nonalcoholic steatohepatitis (NASH), a serious fatty liver disease that can lead to scarring. About 150 adults with NASH and liver scarring (stages 1-3) will take Aramchol or a placebo for up to 72 weeks. The goal is to see …
Matched conditions: NONALCOHOLIC STEATOHEPATITIS (NASH)
Phase: PHASE3 • Sponsor: Galmed Research and Development, Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC